Denali Therapeutics Inc. (DNLI) return on equity (ROE)
Denali Therapeutics Inc. (DNLI) earned a return on equity of -50.6% in fiscal 2025 (the year ended December 31, 2025). That is 16.2 percentage points lower than the -34.4% of fiscal 2024. Figures as of 17 Nov 2026, 21:30 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- -50.6%
- Change on fiscal 2024
- −16.2 pts
- Highest on record
- 6.2%fiscal 2020
- Lowest on record
- -50.6%fiscal 2025
- Fiscal years on record
- 92017–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Denali Therapeutics Inc. return on equity (ROE), in more detail
Across the 9 fiscal years on record (2017–2025), the highest was 6.2% in fiscal 2020 and the lowest -50.6% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 8 earlier fiscal years on record, whose median is -24.6%.
Return on equity by fiscal year
Denali Therapeutics Inc. return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | -50.6% | 16.2 pts down | |
| 2024 | -34.4% | 20.3 pts down | |
| 2023 | -14.1% | 17.2 pts up | |
| 2022 | -31.3% | 1.1 pts down | |
| 2021 | -30.2% | 36.4 pts down | |
| 2020 | 6.2% | 56.2 pts up | |
| 2019 | -50.0% | 43.4 pts down | |
| 2018 | -6.6% | 12.3 pts up | |
| 2017 | -18.9% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Denali Therapeutics Inc., figure by figure
- Denali Therapeutics Inc. market cap
- Denali Therapeutics Inc. revenue
- Denali Therapeutics Inc. earnings
- Denali Therapeutics Inc. earnings per share (EPS)
- Denali Therapeutics Inc. P/E ratio
- Denali Therapeutics Inc. P/S ratio
- Denali Therapeutics Inc. P/B ratio
- Denali Therapeutics Inc. free cash flow
- Denali Therapeutics Inc. operating margin
- Denali Therapeutics Inc. dividend
- Denali Therapeutics Inc. shares outstanding
- Denali Therapeutics Inc. total debt
- Denali Therapeutics Inc. cash on hand
- Denali Therapeutics Inc. total assets
- Denali Therapeutics Inc. return on invested capital (ROIC)
Denali Therapeutics Inc. (DNLI) overview: price, valuation and scorecard
Denali Therapeutics Inc. return on equity (ROE): questions and answers
What is Denali Therapeutics Inc.'s return on equity?
Denali Therapeutics Inc. (DNLI) earned a return on equity of -50.6% in fiscal 2025 (the year ended December 31, 2025). That is 16.2 percentage points lower than the -34.4% of fiscal 2024.
Is Denali Therapeutics Inc.'s return on equity high or low compared with its own history?
The fiscal 2025 figure is no higher than in any of the 8 earlier fiscal years on record, whose median is -24.6%.
What are the highest and lowest return on equity figures on record for Denali Therapeutics Inc.?
Across the 9 fiscal years on record (2017–2025), the highest was 6.2% in fiscal 2020 and the lowest -50.6% in fiscal 2025.
How is Denali Therapeutics Inc.'s return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Denali Therapeutics Inc. (DNLI) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/DNLI/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.